If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMorgan Sindall Group Regulatory News (MGNS)

Share Price Information for Morgan Sindall Group (MGNS)

Share Price is delayed by 15 minutes
Get Live Data
5,085.00    70.00 (1.40%)
Bid:
5,100.00
Ask:
5,105.00
Spread: 5.00 (0.098%)
Market Cap: £2.37b
MGNS Live PriceLast checked at - London Stock Exchange

Intraday Morgan Sindall Group Share Chart

AGM Voting Update

4 Sep 2023 12:51

RNS Number : 3096L
Morgan Sindall Group PLC
04 September 2023
 

Morgan Sindall Group plc

Legal Entity Identifier (LEI) number: 2138008339ULDGZRB345

 

4 September 2023

Morgan Sindall Group plc ("the Company")

 

Update on response to 2023 AGM voting outcome

 

At our Annual General Meeting ('AGM') held on 4 May 2023, resolution 3 (Approval of the Directors' Remuneration Policy) was supported by a large majority of shareholders but received less than 80% support overall.

 

In advance of the 2023 AGM, the Remuneration Committee (the 'Committee') undertook a detailed engagement with the Company's largest shareholders in relation to the remuneration proposals, and had amended the final Remuneration Policy design in response to feedback received. Following the 2023 AGM, the Committee reached out to the Company's largest shareholders to continue the dialogue and listen to their views - and in particular to understand why those who either abstained or voted against the Directors' Remuneration Policy ('the 'Policy') had done so.

 

The Committee received responses from eight investors, the majority of whom reconfirmed support for the Policy and the management team. 

 

One shareholder raised the annual bonus deferral requirement and 2nd-year phasing down of the post-employment shareholding requirement as their reason for not supporting the resolution. In both cases the Committee is comfortable that its current approach supports appropriate alignment of executive and shareholder interests. In respect of the annual bonus deferral requirement, the Committee also considers this requirement appropriate given the current shareholdings of incumbent Executive Directors. However, the Committee will reconsider both of these Policy design features as part of the next Policy review.

 

The Committee also received feedback from two shareholders that their voting had reflected the 'against' recommendation from one of the major proxy voting agencies, which itself was primarily a result of the simultaneous increases to the Policy headroom available under the annual bonus and LTIP schemes. On this matter, the Committee maintains its view that the Policy should be sufficiently flexible to last for a full triennial review period rather than needing to revert to shareholders to seek incremental changes, and reiterates its commitment to write out to major shareholders in advance of using the increased maximum opportunities under either of the variable incentives.

 

Another shareholder requested that the Committee provide a full explanation in its Remuneration Report of the rationale for the adoption of any increase to the executive directors' incentive opportunities in future years, particularly in relation to the achievement of key strategic objectives, and this feedback is consistent with the current thinking of the Committee.

 

The Committee continues to be grateful for the feedback received and the two-way engagement with major shareholders. Given overall majority support was obtained for the Policy resolution, it is not proposed to make any further changes to the approach to remuneration that was set out in the 2022 Annual Report. The Company will, however, continue to keep the Policy under review over the coming years and welcomes ongoing dialogue with shareholders and proxy advisers.

 

 

Enquiries:

Clare Sheridan, Company Secretary +44 (0) 20 7307 9200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFZLFBXKLEBBF
Date   Source Headline
1st Nov 202311:14 amRNSTotal Voting Rights
26th Oct 20234:43 pmRNSHolding(s) in Company
20th Oct 20239:05 amRNSBlock listing Interim Review
10th Oct 202311:44 amRNSAdditional Listing
12th Sep 20233:12 pmRNSHolding(s) in Company
4th Sep 202312:51 pmRNSAGM Voting Update
1st Sep 20239:45 amRNSTotal Voting Rights
22nd Aug 20233:56 pmRNSAdditional Listing
10th Aug 202311:50 amRNSDirector/PDMR Shareholding
10th Aug 202311:45 amRNSDirector/PDMR Shareholding
2nd Aug 20236:30 pmRNSResults for the Half Year (HY) Ended 30 June 2023
1st Aug 202311:13 amRNSTotal Voting Rights
10th Jul 20237:00 amRNSNotice of Half Year Results
3rd Jul 202310:37 amRNSTotal Voting Rights
29th Jun 20237:00 amRNSTrading Update
14th Jun 20232:10 pmRNSAdditional Listing
14th Jun 20239:13 amRNSHolding(s) in Company
12th Jun 20233:50 pmRNSHolding(s) in Company
1st Jun 20239:16 amRNSTotal Voting Rights
31st May 20234:10 pmRNSHolding(s) in Company
10th May 202311:19 amRNSAdditional Listing
5th May 20232:38 pmRNSHolding(s) in Company
4th May 202312:44 pmRNSResult of AGM
4th May 20237:00 amRNSTrading Update
20th Apr 202310:24 amRNSBlock listing Interim Review
23rd Mar 20231:51 pmRNSAnnual Financial Report
21st Mar 20234:24 pmRNSAdditional Listing
16th Mar 20233:34 pmRNSDirector/PDMR Shareholding
16th Mar 20231:52 pmRNSDirector/PDMR Shareholding
14th Mar 20237:00 amRNSUK Government Self Remediation Contract
13th Mar 20232:40 pmRNSDirector/PDMR Shareholding
3rd Mar 202311:58 amRNSDirector/PDMR Shareholding
3rd Mar 202311:57 amRNSDirector/PDMR Shareholding
2nd Mar 20234:42 pmRNSDirector/PDMR Shareholding
2nd Mar 20234:41 pmRNSDirector/PDMR Shareholding
1st Mar 202311:28 amRNSTotal Voting Rights
23rd Feb 20237:00 amRNSFinal Results
6th Feb 20237:00 amRNSNotice of Full Year Results
1st Feb 20231:04 pmRNSTotal Voting Rights
25th Jan 20232:59 pmRNSHolding(s) in Company
3rd Jan 20231:56 pmRNSTotal Voting Rights
12th Dec 20228:25 amRNSHolding(s) in Company
5th Dec 20223:37 pmRNSHolding(s) in Company
2nd Dec 20229:06 amRNSTotal Voting Rights
7th Nov 20224:08 pmRNSAGM Voting Update
2nd Nov 20227:00 amRNSTrading Update
1st Nov 20221:49 pmRNSTotal Voting Rights
20th Oct 202211:00 amRNSBlock listing Interim Review
18th Oct 20221:16 pmRNSAdditional Listing
3rd Oct 20221:51 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.